ÓSKARE-CAPITAL
ÓSKARE CAPITAL SAS today launches ÓSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in medicine, engineering, chemistry, venture capital, and intellectual property.
“Based on my partnership with the ÓSKARE CAPITAL team over the last 9 months, I am convinced that Europe has the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry,” said Bruce Linton, Co-founder and non- Executive Chairman, ÓSKARE CAPITAL, and former CEO and Founder, Canopy Growth. "The ÓSKARE CAPITAL team’s strong scientific background and proven track record in pharma, venture capital and IP protection leverages proprietary deal flow and knowledge of the ecosystem to be successful".
The fund will invest in a diversified portfolio of companies with disruptive technology and strong barriers to entry. The team is supported by a highly experienced senior advisory board (https://oskarecapital.com/team/ ) that provides critical expertise and expands its network. ÓSKARE Fund I is ESG compatible.
Medical grade cannabinoid-based products are already approved and used in Europe to treat conditions such as epilepsy, multiple sclerosis and chronic pain. Now the science and the medical community are driving opportunities in human as well as animal health and wellness.
The team at ÓSKARE CAPITAL has access to leading research teams and companies that have identified new cannabinoid molecules and formulations with therapeutic potential for medical conditions such as anxiety and depression, cancer, autism, ADHD, cardiovascular and inflammatory skin conditions, among others. The fund will invest in the entire value chain as well as look to valorise hemp and cannabis biomass for new sustainable material applications.
The team has already performed a first investment in Denmark’s Octarine Bio .
Innovation and R&D are at the core of EU and UK value generation and core to the Fund opportunity. Cannabinoids will disrupt global markets from food to pharma and ÓSKARE CAPITAL will be the early investor on this wave.
About ÓSKARE CAPITAL SAS – oskarecapital.com
ÓSKARE CAPITAL SAS is a French company which has the French status of CIF (Financial Investment Advisor), ORIAS number 20001206 and regulated by the AMF.
About ÓSKARE FUND I
ÓSKARE Fund I, advised by ÓSKARE CAPITAL SAS, is set up so that investors can readily access innovative opportunities in this space with the protection and transparency an AIFM compatible fund provides. Regulated by the Central Bank of Ireland, Crossroads Capital Management Limited will act as an alternative investment fund manager.
About Crossroads Capital Management Limited – www.crossroadscapital.ie
Crossroads Capital Management Limited, majority owned by Hauck & Aufhäuser Fund Services S.A., is authorised and regulated by the Central Bank of Ireland as a UCITS management company and alternative investment fund manager (AIFM).
This press release is not a marketing communication in the European Union member states or non-member states. This press release is not an offer of securities, products, instruments or services for sale in the United States. We do not make representation that information presented is appropriate for use in all jurisdictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005098/en/
Social Media:
https://www.facebook.com/%C3%93skare-Capital-102537244481166/?view_public_for=102537244481166
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom